AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

PEPE Prices Rise in South Korea After Upbit Listing News ...